This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferguson, R. E. Articles by Banks, R. E. Search for Related Content PubMed PubMed Citation Articles by Ferguson, R. E. Articles by Banks, R. E.

Resistance to the Tubulin-Binding Agents in Renal Cell Carcinoma: No Mutations in the Class I ß-Tubulin Gene but Changes in Tubulin Isotype Protein Expression

Authors' Affiliations: ¹ Cancer Research UK Clinical Centre at Leeds, ² Cancer Research UK Mutation Detection Facility, and ³ Department of Urology, St. James's University Hospital, Leeds, United Kingdom

Requests for reprints: Rosamonde Banks, Cancer Research UK Clinical Centre, St. James's University Hospital, Beckett Street, Leeds LS9 7TF, United Kingdom. Phone: 44-113-2064927; Fax: 44-113-2429886; E-mail: r.banks{at}leeds.ac.uk.

Purpose: The primary purpose of this study was to determine whether mutations of the class I ß-tubulin gene may be implicated in the inherent resistance to tubulin-binding agents (TBA) in renal cancer, with a small number of samples and cell lines also being examined for class I and III ß-tubulin isotype protein expression.

Experimental Design: DNA was extracted from 90 renal tumors and the class I ß-tubulin gene analyzed for mutations. For each sample, eight PCRs were used to cover the complete coding sequence with intronic primers ensuring highly homologous pseudogenes were not coamplified. Additionally, expression levels of class I and III ß-tubulin isotypes in 17 matched normal and malignant renal samples and a panel of renal cell carcinoma cell lines with differing intrinsic resistance to the TBAs was examined by Western blotting.

Results: Four polymorphic sequence changes of the class I ß-tubulin gene were identified with no mutations. Class I protein expression levels were higher in tumor tissue versus normal tissue, whereas class III expression showed no consistent change. In renal cancer cell lines, a significant correlation between class III isotype expression and vinblastine sensitivity was observed.

Conclusions: These results do not support a role for mutations in the class I ß-tubulin gene in the intrinsic resistance of renal cancer to TBAs. Class III isotype expression may be implicated in resistance in vitro but in vivo, changes in class I isotype expression in renal cell carcinoma tissue may support a role in resistance to the TBAs and warrants further investigation.

Key Words: renal cancer • chemotherapy • mutation • ß-tubulin • isotype

This article has been cited by other articles:

				C. Dumontet, M. A. Jordan, and F. F.Y. Lee Ixabepilone: targeting {beta}III-tubulin expression in taxane-resistant malignancies Mol. Cancer Ther., January 1, 2009; 8(1): 17 - 25. [Abstract] [Full Text] [PDF]